Screener
Collegium Pharmaceutical, Inc. COLL Belbuca — 2028
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Years ended December 31, | Jornay PM | Azstarys | Belbuca | Symproic | Total |
|---|---|---|---|---|---|
| 2026 | $41,915 | $27,283 | $37,695 | $3,643 | $110,536 |
| 2027 | 83,829 | 54,567 | — | 7,285 | 145,681 |
| 2028 | 83,829 | 54,567 | — | 7,285 | 145,681 |
| 2029 | 83,829 | 54,567 | — | 7,285 | 145,681 |
| 2030 | 83,829 | 54,567 | — | 7,285 | 145,681 |
| Thereafter | 104,783 | 381,969 | — | 6,072 | 492,824 |
| Remaining amortization expense | $482,014 | $627,520 | $37,695 | $38,855 | $1,186,084 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s belbuca — 2028?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2028 of $0 in Q2 2026.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — 2028?
- Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s belbuca — 2028 has grown at a -0.3% compound annual growth rate (CAGR), from $303.67M to $301.57M.
- What does belbuca — 2028 mean?
- The projected amortization expense specifically allocated to Belbuca-related intangible assets for the fiscal year 2028. It serves as a component of long-term financial forecasting and valuation of the product's intangible asset base.
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — 2028.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude